Belgian medtech startup Nuclivision has attracted €5M in funding, a move expected to advance its AI-powered Nuclarity software for PET imaging. The company, established in 2022, stands at the intersection of digital innovation and healthcare technology. Nuclivision’s recent capital injection, co-led by LUMO Labs and Heran Partners with participation from imec.istart future fund, marks an important moment in the evolution of AI integration within medical imaging. Fresh insights indicate that developments like these are setting a consistent pace for AI adoption in clinical settings.
Earlier reports noted Nuclivision’s commitment to reducing scan duration and radiation risk during PET procedures, aligning with broader trends in European deeptech investments. Additional accounts from various sources emphasized the rising importance of AI in reducing radiotracer usage and optimizing patient care, reinforcing the credibility of Nuclivision’s objectives.
How does Nuclarity improve imaging?
Nuclarity software directly addresses PET scan limitations by lowering both scan time and the dose of radioactive tracers.
“Medical imaging is at an inflection point,” stated the company’s CEO, Maarten Larmuseau.
The software maintains diagnostic accuracy while mitigating health and cost concerns associated with high radiotracer exposure.
What does the funding mean for market expansion?
The secured funds facilitate regulatory approvals and prepare Nuclivision for a European market launch, with plans set for future entry into the U.S. market this year.
“Nuclivision is uniquely positioned in the field of AI-driven image enhancement for PET scans with the Nuclarity platform,” commented Geoffrey D’hondt of Heran Partners.
The investment is not only a financial boost but also provides the startup with strategic business expertise and a widened network.
Additional support from investment partners underscores the broader industry confidence in integrating AI to refine medical imaging.
“The completion of the regulatory approval process marks the beginning of a new growth phase,” explained Sven Bakkes from LUMO Labs.
Similarly, Kris Vandenberk of imec.istart future fund expressed optimism over establishing new standards in PET imaging efficiency.
Observations across multiple analyses suggest that while healthcare innovation faces regulatory hurdles, its momentum remains robust. Readers can note that the emphasis on operational efficacy and reduced environmental impact may drive future applications in nuclear medicine settings.
The financial boost and supportive expert opinions foster an environment conducive to integrating advanced imaging solutions within healthcare systems, providing additional avenues for improved clinical outcomes and cost management.
